NEW YORK, April 10, 2020 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the board of directors of Neon
Therapeutics, Inc. ("NTGN" or the "Company") (NASDAQ: NTGN) in
connection with the proposed acquisition of the Company by BioNTech
("BNTX") (NASDAQ: BNTX). Under the terms of the acquisition
agreement, NTGN shareholders will receive 0.063 American Depositary
Shares issued by BNTX ("ADS") (each ADS representing one ordinary
share of BNTX) in exchange for each share of NTGN common stock that
they own. At the consummation of the proposed acquisition,
NTGN will merge with Endor Lights, Inc., a wholly-owned
subsidiary of BNTX, and itself become a wholly-owned subsidiary of
BNTX.
If you own shares of Neon Therapeutics and
wish to discuss this investigation, or have any questions
concerning this notice or your rights or interests, visit our
website:
https://weisslawllp.com/neon-therapeutics-inc/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
NTGN's board was obligated to maximize shareholder value prior
to entering into the acquisition agreement. Notably, the
average target price for NTGN shares is $8.58, well above the implied per-share value of
the merger consideration.
Given these facts, WeissLaw is investigating whether the
proposed acquisition undervalues the Company, and whether all
material information related to the proposed acquisition is fully
and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-neon-therapeutics-inc-301038947.html
SOURCE WeissLaw LLP